Cerastes cerastes venom toxins (CcV)

Cerastes cerastes venom toxins comprise a complex mixture of bioactive proteins and peptides secreted by the Saharan horned viper, native to North Africa and the Middle East [1, 8]. The venom proteome is dominated by several key protein families, including phospholipases A2 (PLA2), snake venom metalloproteinases (SVMPs), snake venom serine proteinases (SVSPs), disintegrins, and C-type lectin-like proteins [2, 10]. These toxins primarily target the hemostatic system, causing severe coagulopathy, hemorrhage, and platelet aggregation or inhibition, which can lead to life-threatening systemic envenomation characterized by microangiopathic hemolysis and acute renal failure [3, 9]. In clinical practice, these toxins are the therapeutic targets of polyvalent antivenoms such as Favirept and Antivipmyn Africa, which neutralize the venom's enzymatic and toxic activities [14]. Beyond their pathological effects, individual components like L-amino acid oxidases (LAAOs) and disintegrins are being investigated as potential therapeutic leads for cancer treatment due to their ability to induce apoptosis in various tumor cell lines [5, 12].

Other names

Saharan horned viper venomEgyptian sand viper venomDesert horned viper venomCc venomCerastes cerastes toxins

The primary mechanism of action for drugs targeting these toxins involves the binding of specific antibodies (antivenom) to the toxic proteins, thereby neutralizing their enzymatic activity and preventing their interaction with physiological substrates such as fibrinogen and platelets [3, 14]. Experimental inhibitors like Varespladib target the active site of phospholipase A2 enzymes to prevent membrane damage and systemic toxicity [7, 11].